{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Abeona Therapeutics, Inc.
Is Abeona Therapeutics, Inc. overvalued or undervalued?
As of August 12, 2024, Abeona Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial metrics, including a Price to Book Value of 8.33 and a negative ROE of -164.21%, significantly underperforming compared to peers like Talaris Therapeutics and Protalix Biotherapeutics.
Who are in the management team of Abeona Therapeutics, Inc.?
As of March 2022, the management team of Abeona Therapeutics, Inc. includes Ms. Christine Silverstein (Director), Mr. Paul Mann (Independent Director), and Dr. Todd Wider (Independent Director).
What does Abeona Therapeutics, Inc. do?
Abeona Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare genetic diseases. It has a market cap of approximately $306.94 million and reported a net profit loss of $12 million as of March 2025.
How big is Abeona Therapeutics, Inc.?
As of Jun 18, Abeona Therapeutics, Inc. has a market capitalization of 306.94 million and reported net sales of 0.00 million with a net profit of -44.18 million over the last four quarters. Shareholder's funds are 44.03 million, and total assets are 108.93 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
